AVEO

AVEO is a Massachusetts-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer.

Business Model:

Revenue: $94.3M

Employees: 51-200

Detailed AVEO Information

Geographic Data

AVEO headquarters map

Address: 30 Winter Street

City: Boston

State: MA

Zip: 02108

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$55M

Raised Total:

$379M

Metrics

3,148,562Website Global Rank

5,190Website Monthly Traffic

Twitter Followers

Description

AVEO is a Massachusetts-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer.

Contact Phone:
+18574000101

Contact Email:

AVEO went public on 3/12/2010 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
3/12/2010

IPO Valuation:
$415M

Ticker Symbol:
AVEO

IPO Price:
$9/share

Amount Raised:
$81M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
5/2011 Post-IPO Equity $7.5M
11/2010 Post-IPO Equity $60.8M
5/2016 Post-IPO Equity 3 $17M New Leaf Venture Partners
Perceptive Advisors
New Enterprise Associates
New Enterprise Associates
New Leaf Venture Partners
Perceptive Advisors
New Enterprise Associates
New Enterprise Associates
1/2016 Post-IPO Equity 1 - New Enterprise Associates
New Enterprise Associates
10/2003 Series B 7 $42.7M Venrock
Prospect Venture Partners
Oxford Bioscience Partners
MPM Capital
Highland Capital Partners
Greylock
Flagship Pioneering
Venrock
Prospect Venture Partners
Oxford Bioscience Partners
MPM Capital
Highland Capital Partners
Greylock
Flagship Pioneering
5/2002 Series A 4 $15M Venrock
Prospect Venture Partners
MPM Capital
Greylock
Venrock
Prospect Venture Partners
MPM Capital
Greylock
8/2020 Post-IPO Debt 1 $35M Hercules Capital
Hercules Capital
3/2017 Post-IPO Equity $15.5M
3/2021 Post-IPO Equity $55.2M
6/2020 Post-IPO Equity $51.1M
1/2013 Post-IPO Equity $53.8M
5/2007 Series D 1 $53M Venrock
Venrock
7/2009 Venture Round 1 $20M OSI Pharmaceuticals
OSI Pharmaceuticals
6/2010 Post-IPO Equity $25M Hercules Technology Growth Capital, Inc.
6/2011 Post-IPO Equity $104.3M
8/2020 Post-IPO Debt $45M Hercules Capital, Inc.
6/2017 Post-IPO Debt $14M Hercules Capital, Inc
5/2011 Unattributed $7.5M
5/2005 Series C 5 $5M Venrock
Prospect Venture Partners
MPM Bio IV NVS Strategic Fund
Highland Capital Partners
Applied Genomic Technology Capital Funds
Venrock
Prospect Venture Partners
MPM Bio IV NVS Strategic Fund
Highland Capital Partners
Applied Genomic Technology Capital Funds
5/2010 Post-IPO Equity 1 $25M Hercules Capital
Hercules Capital
1/2016 Post-IPO Equity 1 - New Enterprise Associates
New Enterprise Associates
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research